Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease

Abstract

Fabry disease is an inborn error of glycosphingolipid metabolism caused by the deficiency of lysosomal alpha-galactosidase A (alpha-Gal A). We have established transgenic mice that exclusively express human mutant alpha-Gal A (R301Q) in an alpha-Gal A knock-out background (TgM/KO mice). This serves as a biochemical model to study and evaluate active-site specific chaperone (ASSC) therapy for Fabry disease, which is specific for those missense mutations that cause misfolding of alpha-Gal A. The alpha-Gal A activities in the heart, kidney, spleen, and liver of homozygous TgM/KO mice were 52.6, 9.9, 29.6 and 44.4 unit/mg protein, respectively, corresponding to 16.4-, 0.8-, 0.6- and 1.4-fold of the endogenous enzyme activities in the same tissues of non-transgenic mice with a similar genetic background. Oral administration of 1-deoxygalactonojirimycin (DGJ), a competitive inhibitor of alpha-Gal A and an effective ASSC for Fabry disease, at 0.05 mM in the drinking water of the mice for 2 weeks resulted in 13.8-, 3.3-, 3.9-, and 2.6-fold increases in enzyme activities in the heart, kidney, spleen and liver, respectively. No accumulation of globotriaosylceramide, a natural substrate of alpha-Gal A, could be detected in the heart of TgM/KO mice after DGJ treatment, indicating that degradation of the glycolipid in the heart was not inhibited by DGJ at that dosage. The alpha-Gal A activity in homozygous or heterozygous fibroblasts established from TgM/KO mice (TMK cells) was approximately 39 and 20 unit/mg protein, respectively. These TgM/KO mice and TMK cells are useful tools for studying the mechanism of ASSC therapy, and for screening ASSCs for Fabry disease.

Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease

“…Further proof-of-concept, suggesting that alteration in protein conformation within cells in vitro and in vivo may be a valid approach to alter protein function, comes from studies of Fabry disease (161,162). A recent review summarizes the use of small molecules to modulate the structure and function of various proteins of biological importance (163).…”

G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo

“…It is becoming well recognized that mutations of receptors, enzymes, and ion channels frequently result in protein misfolding and subsequent retention by the cell's QCS (Tamarappoo and Verkman 1998;Burrows et al, 2000;Janovick et al, 2002;Leañ os-Miranda et al, 2002;Ulloa-Aguirre et al, 2003Bernier et al, 2004a,b;Ishii et al, 2004;Conn and Janovick, 2005;Loo et al, 2005;Yam et al, 2005;Pastores and Barnett, 2005;Suzuki, 2006;Ulloa-Aguirre and Conn, 2006;Wang et al, 2006). Misfolding can result in protein molecules that retain intrinsic function yet become misrouted within the cell and, for reasons of mislocation only, cease to function normally and result in disease.…”

Histidine-Tagged Shiga Toxin B Subunit Binding Assay: Simple and Specific Determination of Gb3 Content in Mammalian Cells

“…Recently, we described a new therapeutic strategy, active-site specific chaperone therapy for this disease. 34,35) The assay method established by this study will provide a crucial benefit for the preclinical and clinical trial of this treatment strategy. Knowledge of the physiological and pathological role of Gb3 will increase using this assay method.…”